SOURCE: BioProgress PLC

April 30, 2007 02:02 ET

BioProgress PLC - Technology Update

Cambridgeshire -- (MARKET WIRE) -- April 30, 2007 --For Immediate Release 30 April 2007


                          BioProgress plc

     Technology Update and launch of new Technology - FastWrapTM

London, UK, 30 April 2007: BioProgress plc ('BioProgress' or the 'Company') (AIM: BPRG; NASDAQ: BPRG), the specialty pharma and healthcare company, today announces a technology update and the launch of a new tablet technology, FastWrapTM using the TabWrapTM enabling technology platform.

Commercialisation of the TabWrapTM enabling technology platform has recently passed some key internal milestones and is now in the final process qualification program. The system has been shown to operate within its technical specification and produces 100,000 tablets per hour. In parallel, new variants of XGELTM have been developed giving further differential advantages to certain products utilising the TabWrapTM system.

The Company remains on target to be producing TabWrapTM enhanced tablets for launch into the market by the end of 2007. These products will be initially launched within the US market and aimed at analgesic indications. The undisclosed molecule has a US market size of $1.4billion (Datamonitor, estimates for 2007) and offers a unique competitive advantage over the leading brand which accounts for 14.1% of the total market. The Company plans to launch a FastWrapTM version, as a line extension in 2008.

The SoluleavesTM suite of technologies will be delivering new products during Q2 2007. These include launches of non-regulated products which will be marketed through the Group's sales and marketing subsidiary Dexo. The core US market will see the launch of the Company's local anaesthetic product for sore mouths and a SoluleavesTM thin strip which will be marketed under the AccuhistTM allergy brand with its partner Tiber Laboratories. The market for lozenge products in the cough/cold indication is $1.7 billion (Datamonitor 2007) with the US accounting for $506.3m of sales. The Group's US division will be launching a prescription only SoluleavesTM line extension of its Ah-Chew brand for the 2007 cough/cold season.

The Group is progressing on target with its patented smoking cessation product. The product is a fast release stabilised oral film strip product. The global market size for Over the Counter (OTC) smoking cessation products is $2.1 billion. In addition, the prescription only market for these products in the US alone represents an additional $300m. The key markets for smoking cessation are the US, Japan and Germany. Alternative dosage forms to traditional patches and chewing gums are the fastest growth areas. The Group expects partner discussions to complete in the very near term.

SoluPolTM products are progressing ahead of plan with three products currently in pre-registration development, one in partnership and the other two for Dexo's own products. One is in the area of analgesia and the Company anticipate that regulatory filings will be made during H2 2007. The molecule in question currently has a market value of $1.3 billion with significant market share in Italy, Germany and the US. Dexo's second development is in the area of gastro-intestinal disease and the Company expects to be able to file for regulatory approval by the end of 2007.

FastWrapTM is a new technology that allows the rapid disintegration of coated tablets thereby allowing for a faster onset of action of a drug. Using the Company's patented novel tablet core technology, BioProgress is able to utilise the novel TabWrapTM production system to create coated tablets which will disintegrate and dissolve more rapidly than traditional techniques. In addition, film-flavoured orally disintegrating tablets are also able to be produced. The current worldwide market for orally disintegrating tablets is over $700m and growing at 31% per annum.

The system is designed to create competitive advantages within the OTC drugs market where speed of onset of action is a key consideration. The technology is being targeted within the analgesic and cough/cold therapeutic areas. The Global OTC analgesic market is worth $6.2 billion in 2007 (Datamonitor) with the US, UK and Japan being the largest three single markets. The main actives used with existing therapies are paracetamol/acetaminophen, aspirin and ibuprofen. The global OTC cough / cold market is worth $10.5 billion with USA, Japan and Germany being the three largest single markets.

The FastWrapTM technology has been developed as a response to requests from new commercial partners. BioProgress additionally intends to use this technology for its own products to create differential marketing benefits, particularly within the US market.

Richard Trevillion, Chief Executive Officer, BioProgress, said:

"The launch of an additional technology within our portfolio is another important step in creating a compelling enabling technology range for our own products whilst enhancing our ability to work with partners. Speed of onset of action is an important weapon in the war against illness and we are now able to compete effectively within the market place.

"The team have worked hard to ensure that the TabWrapTM technology is on target to deliver both our partners and our own proprietary product launch and development targets. Our core developments are going to plan and we remain confident that our products will offer the patient a differential advantage.

"The Group also expects revenue generation to be in line with expectations, and administration costs to remain at similar levels reported by the company for the full year in 2006."


For further information:

BioProgress Plc                   + 44 (0) 20 7098 9881

Richard Trevillion, CEO

Steve Martin, CDO

Hiral Patel, CFO

Buchanan Communications           + 44 (0) 20 7466 5000

Rebecca Skye Dietrich

Mark Court

About BioProgress

BioProgress plc is an innovative specialty pharmaceutical and healthcare business based around its platform technologies in polymer and film systems. Listed on London's AIM in May 2003 and on US NASDAQ in October 2004, the company has over 80 patents granted or in application within 24 patent families and has product development agreements and strategic alliances with several global companies. As a virtually integrated business, BioProgress has acquired sales and marketing resources within Europe and the US as a launch mechanism for its own pharmaceutical products. The business continues to develop innovative delivery mechanisms using its XGELTM polymer technology, replacing the need to use animal-derived gelatine in pharmaceutical and healthcare products. For further information please go to www.bioprogress.com

Forward-Looking Information.

The Ordinary Shares of BioProgress plc are registered under the US Securities and Exchange Act of 1934. To the extent that this announcement contains certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, this paragraph applies. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may vary materially from the expectations contained in the forward-looking statements. The forward-looking statements in this release include statements addressing future financial and operating results and the timing and benefits of the reorganisation. Detailed information about factors pertinent to the business of the company that could cause actual results to differ is set forth in the Company"s filings with the Securities and Exchange Commission. The Company is under no obligation to (and expressly disclaim any such obligation to) update or alter its forward-looking statements whether as a result of new information, future events or otherwise. This announcement is for information only and does not constitute an offer or invitation to acquire or dispose of any securities or investment advice. The distribution of the announcement and/or issue of securities in certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes are required to inform themselves about and to observe such restrictions.



                      This information is provided by RNS
            The company news service from the London Stock Exchange